David Mott - Epizyme Independent Director
| EPZMDelisted Stock | USD 1.47 0.00 0.00% |
Director
Mr. David M. Mott is an Independent Chairman of the Board of the Company. Mr. Mott has served as a general partner of New Enterprise Associates, Inc., an investment firm focused on VC and growth equity investments and a holder of more than 5 percent of our voting securities, since September 2008, where he leads the healthcare investing practice. From 1992 until 2008, Mr. Mott worked at MedImmune, Inc., or MedImmune, a biotechnology company and subsidiary of AstraZeneca Plc, or AstraZeneca, and served in numerous roles during his tenure, including most recently as Chief Executive Officer from October 2000 to July 2008. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca from June 2007 to July 2008 following AstraZenecas acquisition of MedImmune in June 2007. Mr. Mott also serves as the Chairman of the board of directors of TESARO, Ardelyx, Inc. and Adaptimmune and serves on the boards of several private biopharmaceutical companies since 2016.
| Age | 52 |
| Tenure | 8 years |
| Phone | 617 229-5872 |
| Web | www.epizyme.com |
Epizyme Management Efficiency
The company has return on total asset (ROA) of (38.96) % which means that it has lost $38.96 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (352.37) %, meaning that it created substantial loss on money invested by shareholders. Epizyme's management efficiency ratios could be used to measure how well Epizyme manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 254.44 M in liabilities. Epizyme has a current ratio of 5.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Epizyme until it has trouble settling it off, either with new capital or with free cash flow. So, Epizyme's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Epizyme sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Epizyme to invest in growth at high rates of return. When we think about Epizyme's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Shahid Burki | NetSol Technologies | 75 | |
| Sanjay Mehrotra | Western Digital | 55 | |
| Charles Doyle | Q2 Holdings | 84 | |
| Susan Bostrom | Cadence Design Systems | 57 | |
| Paula Price | Western Digital | 55 | |
| Ahmed Nawaz | Digi International | 66 | |
| Henry DeNero | Western Digital | 70 | |
| Guy Jackson | Digi International | 72 | |
| Lisa Su | Analog Devices | 48 | |
| Sam Lazarakis | Digi International | N/A | |
| Chris Heim | Digi International | N/A | |
| George Scalise | Cadence Design Systems | 81 | |
| William Priesmeyer | Digi International | 70 | |
| James Champy | Analog Devices | 75 | |
| Carl Schaper | Q2 Holdings | 66 | |
| James Offerdahl | Q2 Holdings | 64 | |
| Jeffrey Bilbrey | NetSol Technologies | 43 | |
| Kathleen Cote | Western Digital | 69 | |
| Kenneth Millard | Digi International | 66 | |
| Mark Little | Analog Devices | 65 | |
| James Hedges | Park City Group | N/A | |
Management Performance
| Return On Equity | -352.37 | |||
| Return On Asset | -38.96 |
Epizyme Leadership Team
Elected by the shareholders, the Epizyme's board of directors comprises two types of representatives: Epizyme inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epizyme. The board's role is to monitor Epizyme's management team and ensure that shareholders' interests are well served. Epizyme's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epizyme's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Shih, Vice President - Business Development | ||
| Robert Bazemore, CEO and President and Director | ||
| Richard Pops, Independent Director | ||
| Kevin Conroy, Director | ||
| Pamela Strode, Vice President - Regulatory Affairs and Quality Assurance | ||
| Andrew Allen, Director | ||
| Joseph Beaulieu, Principal Accounting Officer, Controller | ||
| Robert Gould, CEO and President Secretary and Director | ||
| Manisha Pai, IR Contact Officer | ||
| Matthew Ros, COO | ||
| Michael Boretti, Vice President - Business Development | ||
| Stephen Garbacz, Principal Accounting Officer and Executive Director of Fin. | ||
| Shefali Agarwal, Chief Medical Officer | ||
| Susan Graf, Chief Business Officer | ||
| Jason Fredette, Vice President of Investor Relations | ||
| Robert Copeland, President of Research and Chief Scientific Officer | ||
| Suzanne Fleming, Senior Vice President - Finance, Principal Accounting Officer, Treasurer | ||
| Michael Giordano, Director | ||
| Carl Goldfischer, Independent Director | ||
| Paolo Tombesi, CFO | ||
| Kenneth Bate, Independent Director | ||
| Peter Ho, Chief Development Officer | ||
| Beth Seidenberg, Independent Director | ||
| David Mott, Independent Director | ||
| Andrew Singer, CFO, Executive VP of Fin. and Admin. and Treasurer |
Epizyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Epizyme a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -352.37 | |||
| Return On Asset | -38.96 | |||
| Operating Margin | (582.15) % | |||
| Current Valuation | 334.85 M | |||
| Shares Outstanding | 103.89 M | |||
| Shares Owned By Insiders | 0.58 % | |||
| Shares Owned By Institutions | 90.32 % | |||
| Number Of Shares Shorted | 5.49 M | |||
| Price To Earning | (7.76) X | |||
| Price To Book | 1.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Epizyme in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Epizyme's short interest history, or implied volatility extrapolated from Epizyme options trading.
Pair Trading with Epizyme
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epizyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epizyme will appreciate offsetting losses from the drop in the long position's value.Moving together with Epizyme Stock
| 0.7 | NVO | Novo Nordisk AS Earnings Call This Week | PairCorr |
| 0.65 | NONOF | Novo Nordisk AS | PairCorr |
Moving against Epizyme Stock
| 0.88 | BA | Boeing Financial Report 24th of July 2024 | PairCorr |
| 0.86 | AAPL | Apple Inc Earnings Call This Week | PairCorr |
| 0.76 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.7 | WXIBF | WuXi Biologics | PairCorr |
| 0.58 | CSLLY | CSL | PairCorr |
The ability to find closely correlated positions to Epizyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epizyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epizyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epizyme to buy it.
The correlation of Epizyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epizyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epizyme moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epizyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Epizyme information on this page should be used as a complementary analysis to other Epizyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Epizyme Stock
If you are still planning to invest in Epizyme check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epizyme's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stocks Directory Find actively traded stocks across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |